Globeflex Capital L P Acquires Shares of 241,298 Emergent Biosolutions Inc. $EBS

Globeflex Capital L P purchased a new position in Emergent Biosolutions Inc. (NYSE:EBS) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 241,298 shares of the biopharmaceutical company’s stock, valued at approximately $2,022,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its position in shares of Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after buying an additional 1,020,582 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Emergent Biosolutions by 12.5% during the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after acquiring an additional 121,583 shares during the period. Legal & General Group Plc acquired a new position in Emergent Biosolutions in the second quarter valued at approximately $31,000. Rhumbline Advisers grew its stake in Emergent Biosolutions by 862.4% during the 2nd quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company’s stock worth $536,000 after buying an additional 75,294 shares during the last quarter. Finally, Jump Financial LLC bought a new position in Emergent Biosolutions during the 2nd quarter worth $352,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Price Performance

NYSE EBS opened at $5.18 on Tuesday. Emergent Biosolutions Inc. has a 12 month low of $4.36 and a 12 month high of $14.06. The firm has a market capitalization of $265.49 million, a PE ratio of -1.46 and a beta of 2.35. The company’s 50 day simple moving average is $7.04 and its 200 day simple moving average is $8.21. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. The firm had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. As a group, equities research analysts forecast that Emergent Biosolutions Inc. will post -4.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a report on Friday. They set an “underweight” rating for the company. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. HC Wainwright decreased their target price on shares of Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Insider Buying and Selling at Emergent Biosolutions

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.